In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

Unisys (NYSE: UIS), a leading global technology solutions provider, has joined the Chicago Quantum Exchange (CQE), launching a partnership aimed at driving industry-specific applications for quantum ...

The hires are a signal of intent from the firm, which has been strengthening its U.S. presence in recent years.

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

The European Molecular Biology Laboratory (EMBL) is Europe's esteemed lab network for research in molecular biology. EMBL is funded by 20 member states an one associate member. EMBL operates in 5 ...

Explore the detailed Molecular Partners AG balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...

CANYON, Texas (KAMR/KCIT) — West Texas A&M Athletics announced that it will partner with BrandU to create and introduce a new secondary logo along with creative sports graphics for gamedays.

Just yesterday, Goldman Sachs CEO David Solomon confirmed that his company’s relationship with Apple could end sooner rather than later. Now, Reuters reports that Apple is in talks with Barclays ...

Walmart steel cage match (although we would totally watch). Instead, Walmart gave its logo a makeover fit for modern times—at least that was the idea. But people, well, they have feelings.

Walmart announced on Monday that it had unveiled a new logo, part of "a comprehensive brand refresh." The U.S.-based retailer boasted in a news release that the new look — its first change ...

Molecular Partners AG leverages a novel DARPin platform for targeted cancer therapies, with promising early-stage candidates like MP0533 and MP0317 in clinical trials. Financially, MOLN has a cash ...